Shionogi's naldemedine receives approval application acceptance in China

Shionogi & Co., Ltd. (TSE:4507) announced that China has accepted its New Drug Application (NDA) for naldemedine tosilate, a treatment for opioid-induced constipation (OIC). Naldemedine, a peripherally acting µ-opioid receptor antagonist (PAMORA) developed by Shionogi, is already available in Japan, the United States, Europe, and Taiwan under the brand names Symproic® and Rizmoic®. This latest development paves the way for naldemedine to address the limited OIC treatment options currently available in China and improve QOL for patients who often face challenges in managing opioid analgesics.